Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study - Wikidata - awgldk - TriplyDB

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

http://www.wikidata.org/entity/Q34240204

about

Approaches to preventative and therapeutic HIV vaccines Role of HLA Adaptation in HIV Evolution Immune-Complexed Adenovirus Induce AIM2-Mediated Pyroptosis in Human Dendritic Cells A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes Age and sex or gender (sex/gender) and HIV vaccine preparedness.Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.Challenges in HIV Vaccine Research for Treatment and Prevention.Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Accelerating HIV-1 Vaccine Efficacy Trials Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083 Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02 Prevention of SHIV transmission by topical IFN-β treatment.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Ebola virus vaccine: benefit and risks of adenovirus-based vectors.Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome.Paediatric HIV infection: the potential for cure.Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.Polyvalent vaccine approaches to combat HIV-1 diversity Complex immune correlates of protection in HIV-1 vaccine efficacy trials.HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.Trained Immunity and Susceptibility to HIV.More Surprises in the Development of an HIV Vaccine.Nonhuman Primate Models and Understanding the Pathogenesis of HIV Infection and AIDS.Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.Conserved HIV Epitopes for an Effective HIV Vaccine.Causal analysis of ordinal treatments and binary outcomes under truncation by death.[Anti-adenovirus humoral immunity: impact on dendritic cell activation].

P2860

Q26764851-8898C4F8-5788-4C8C-A3D7-4F65556169CE Q26772713-F2AD86F5-96E7-4C6A-A51D-10735E1CE27E Q28554212-7F797DF5-7DF5-4750-B20C-15D2FB77455A Q29994671-9DAA7931-6CD4-4306-A864-9792BC59F2C3 Q30096805-9D2C17D5-372E-4BC3-BDF5-B828F8AACD6E Q30202232-0E03979E-72DE-4F53-9538-C7855B11F67C Q33820903-722716B1-DADE-45D7-A261-4BC57D2FAF43 Q33869332-593CDA75-2040-40C1-BACA-9C1D71727EA1 Q33875160-9122E1C1-CD3A-475D-B6B8-E1EB8E21D7FE Q33999615-3F290257-949B-44BF-810B-A403F2AA1C45 Q34148683-68430133-1EAE-4335-B32E-989CE34AB0C7 Q34480617-728A865E-95E1-447D-A312-72F3954E0361 Q34580725-C610EC2E-EA37-4F1B-97BC-661F91D60527 Q35488175-AD51C306-D91E-4FD7-8E4C-0499F3BBE4F1 Q35762443-3878D1DF-C6BC-48BA-8306-07E72C0CFA64 Q35774494-0B76DB35-F147-49A0-82F3-E2D1841E3FA4 Q35917501-70AA86AC-C1B3-4B93-B508-16C864D66090 Q36107127-60D535F5-7302-4F38-9F6F-FE45AA6DCCE6 Q36238314-CA708EA7-8B0F-4E31-9D61-D9EA6D812CF4 Q36487887-A75F5BCA-0585-433C-8BC1-4A7AFB08091A Q37074610-A1A70D59-52B9-4551-91BA-279D0666A5BB Q37150111-6B0A9AF9-4D84-4B78-A124-2E28913A6793 Q37621530-B5BBAEB9-CCF3-48CD-BAC2-D41E147CE693 Q38577875-B851E5C7-4329-4788-A37E-032B0DFA0B18 Q38671545-73D6AB3F-F6E9-4AE6-95D0-1C112F8EF2A9 Q38773102-DB21A441-4EC6-4623-970E-6DC5E4A41A8F Q38982807-9AE19AC8-E76F-4E81-A054-B6CBCB260F53 Q39108740-9129DF17-0AB3-4CA2-BB40-669E379B0A41 Q39108779-AF09A56D-C37D-43C9-97E5-343295F1131C Q40057846-490BBA4B-F8A3-4C3F-B08F-C42AA27F36DA Q40450524-2BE85FA1-78FF-4B4F-8A5B-FF77F38FA787 Q41966671-E19F56A6-14FD-4078-88CC-9FE677B1A600 Q46243818-0C847DE3-9602-4B8A-96A0-B44403CDEB29 Q46296261-762912BC-C3F1-46D0-8F03-780943AFB98F Q47093684-DE4D728E-1D72-4C34-B716-B959E8F4BBA6 Q47901408-199AD500-75AA-4720-8CEF-B753E55B2EB1 Q49485917-73F43DC9-119E-4D96-B562-B6FA0CF8E786

P2860

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

http://www.wikidata.org/entity/Q34240204

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@ast

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@en

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@nl

type

label

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@ast

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@en

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@nl

prefLabel

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@ast

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@en

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@nl

P1433

Q34240204-1A820EB1-BB46-4316-8176-B76840188893

P1476

Q34240204-2D588E91-7B13-4BB5-9EBF-DBA66A6E880D

P2093

Q34240204-183696D4-A629-44FD-8379-54F23E910C91

Q34240204-2E0FE0A8-615A-47D6-9B50-AC2EB23D3A08

Q34240204-3D206186-D0CF-48AB-9CE3-1E648087B19A

Q34240204-512D8156-D6DA-4ACE-BC0C-F10D971D537C

Q34240204-8625C6BA-0641-4A82-9EF3-2AD4E1B5A49F

Q34240204-89D84A30-B5AE-4806-9D72-59C37DA15D6F

Q34240204-8FE89971-F700-4D66-A976-B7221F8E6244

Q34240204-97B13CB2-AD15-4D97-9BFF-C4F7DE6FA693

Q34240204-9BF708AE-CA8B-4762-9F0F-65214EFB914E

Q34240204-B72819BF-FC14-45F0-81F8-A2ED77A580BC

P2860

Q34240204-01B3C821-4D55-49D7-A48B-D5C8A307C5EA

Q34240204-115DE4B9-FFBD-4AFB-B32F-F6D16479E5A6

Q34240204-13BDEA57-1395-4FDA-943D-9A3568EA955F

Q34240204-18F96E6E-72B9-4753-A581-20D86328CBBC

Q34240204-2AA93482-1BF7-4DF5-8E0F-3D02935AC5D6

Q34240204-2FA71C55-C607-434B-AEE5-128E6283DE18

Q34240204-309DB0E5-23B1-4E03-8DBD-1842AB62071B

Q34240204-3116E38C-07A2-4D68-82CF-CDD1441D815C

Q34240204-36992EC4-78ED-4C92-B0DA-F71EBE4B9209

Q34240204-36DAB103-5C76-405F-84A5-EEBDF799B178

P304

Q34240204-EBE86A70-C526-4DD1-A57B-0798FC7135BC

P31

Q34240204-A8F67FF5-7A8D-4810-9FF9-F0A5A1198D1F

P356

Q34240204-E3FE8767-831D-46FE-80C2-0D4F570C180E

P433

Q34240204-1FD6B543-7D31-44FD-A8F2-19A517489F61

P478

Q34240204-5F28B260-4F78-48D9-AEC1-C83BF63D86BD

P50

Q34240204-335D3D44-F322-4B6E-8DA5-D623532CD739

Q34240204-422CECBA-85BC-4DA0-965A-1210CF392ABD

Q34240204-60E11412-524B-4574-BAA6-6E10707F64EF

Q34240204-FF176757-3B7B-46BC-8067-47D374E445D5

P577

Q34240204-9B717BCB-654A-46BC-BBAD-CD93C8DA0FE1

P698

Q34240204-172DA45F-186C-48F2-B38A-8AF09EE249D4

P921

Q34240204-413C7B21-7348-4587-9617-81EF3C1222AA

Q34240204-C908A586-6CC1-4FDE-A13B-2B0C9F263B12

P932

Q34240204-AE4C2320-0D4F-4182-98E0-82A8FC33B7D9

P356

S1473-3099(14)70020-9

P1433

The Lancet Infectious Diseases

P1476

Recombinant adenovirus type 5 ...... ase 2b HVTN 503/Phambili study

@en

P2093

Barbara Metch

http://www.w3.org/2001/XMLSchema#string

Craig Innes

http://www.w3.org/2001/XMLSchema#string

Fatima Laher

http://www.w3.org/2001/XMLSchema#string

Gavin Churchyard

http://www.w3.org/2001/XMLSchema#string

Glenda E Gray

http://www.w3.org/2001/XMLSchema#string

HVTN 503/Phambili study team

http://www.w3.org/2001/XMLSchema#string

Kathryn Mngadi

http://www.w3.org/2001/XMLSchema#string

M Julie McElrath

http://www.w3.org/2001/XMLSchema#string

Maphoshane Nchabeleng

http://www.w3.org/2001/XMLSchema#string

Mary Allen

http://www.w3.org/2001/XMLSchema#string

P2860

Life and death as a T lymphocyte: from immune protection to HIV pathogenesis

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

P304

388-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1473-3099(14)70020-9

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Linda-Gail Bekker

P577

2014-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24560541

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

P932

4174314

http://www.w3.org/2001/XMLSchema#string